99% High Purity Original Powder Finasteride CAS 98319-26-7 for Hair Loss

China 99% High Purity Original Powder Finasteride CAS 98319-26-7 for Hair Loss, Find details about China Finasteride, CAS 98319-26-7 from 99% High Purity Original Powder Finasteride CAS 98319-26-7 for Hair Loss

Model NO.
Finasteride
CAS
98319-26-7
Name
Finasteride
Einecs Number
620-534-3
Mf
C23h36n2o2
MW
372.54
Einecs No.
620-534-3
Melting Point
253
Boiling Point
526.6-626.6
Density
1.005-1.125 g/cm3
Merck
14, 4082
Shelf Life
2 Years
Storage
Store at Rt
Delivery Time
7-10 Days
Trademark
BIOCAR
Transport Package
Foil Bag and Drum
Specification
kg
Origin
Wuhan, Hubei, China
HS Code
29379000
Model NO.
Finasteride
CAS
98319-26-7
Name
Finasteride
Einecs Number
620-534-3
Mf
C23h36n2o2
MW
372.54
Einecs No.
620-534-3
Melting Point
253
Boiling Point
526.6-626.6
Density
1.005-1.125 g/cm3
Merck
14, 4082
Shelf Life
2 Years
Storage
Store at Rt
Delivery Time
7-10 Days
Trademark
BIOCAR
Transport Package
Foil Bag and Drum
Specification
kg
Origin
Wuhan, Hubei, China
HS Code
29379000
99% High Purity Original Powder Finasteride CAS 98319-26-7 for Hair Loss

99% High Purity Original Powder Finasteride CAS 98319-26-7 for Hair Loss
Basic Information
 99% High Purity Original Powder Finasteride CAS 98319-26-7 for Hair Loss

Introduction

Finasteride, sold under the brand names Proscar and Propecia among others, is a medication used to treat hair loss and benign prostatic hyperplasia in men. It can also be used to treat excessive hair growth in women and as a part of hormone therapy for transgender women. It is taken by mouth.

Finasteride is a 5α-reductase inhibitor and therefore an antiandrogen. It works by decreasing the production of dihydrotestosterone (DHT) by about 70%, including in the prostate gland and the scalp.

In addition to DHT, finasteride also inhibits the production of several anticonvulsant neurosteroids including , androstanediol and THDOC.

Adverse effects from finasteride are rare, however some men experience sexual dysfunction, depression, and breast enlargement. In some men, sexual dysfunction may persist after stopping the medication. It may also hide the early symptoms of certain forms of prostate cancer.

Finasteride was patented in 1984 and approved for medical use in 1992. It is available as a generic medication. In 2019, it was the 86th most commonly prescribed medication in the United States, with more than 8 million prescriptions.

99% High Purity Original Powder Finasteride CAS 98319-26-7 for Hair Loss

 

Medical Uses

Finasteride is indicated for the treatment of symptomatic benign prostatic hyperplasia (BPH) in men with an enlarged prostate and for the treatment of male pattern hair loss (androgenetic alopecia) in men.

Enlarged Prostate

Physicians sometimes prescribe finasteride for the treatment of benign prostatic hyperplasia (BPH), informally known as an enlarged prostate. Finasteride may improve the symptoms associated with BPH such as difficulty urinating, getting up during the night to urinate, hesitation at the start and end of urination, and decreased urinary flow. It provides less symptomatic relief than alpha-1 blockers such as tamsulosin and symptomatic relief is slower in onset (six months or more of treatment with finasteride may be required to determine the therapeutic results of treatment). Symptomatic benefits are mainly seen in those with prostate volume > 40 cm3. In long-term studies finasteride but not alpha-1 inhibitors reduce the risk of acute urinary retention (−57% at 4 years) and the need for surgery (−54% at 4 years).[medical citation needed] If the drug is discontinued, any therapeutic benefits are reversed within about 6-8 months.

Scalp Hair Loss

Finasteride is also used to treat male pattern baldness (androgenic alopecia) in men, a condition that develops in up to 80% of Caucasian men. In the United States, finasteride and minoxidil are the only two FDA approved drugs for the treatment of male pattern hair loss as of 2017. Treatment with finasteride slows further hair loss  and provides about 30% improvement in hair loss after six months of treatment, with effectiveness persisting as long as the drug is taken. Taking finasteride leads to a reduction in scalp and serum DHT levels; by lowering scalp levels of DHT, finasteride can maintain or increase the amount of terminal hairs in the anagen phase by inhibiting and sometimes reversing miniaturization of the hair follicle. Finasteride is most effective on the crown but can reduce hair loss in all areas of the scalp. Finasteride has also been tested for pattern hair loss in women; however, the results were no better than placebo. Finasteride is less effective in the treatment of scalp hair loss than dutasteride.

Prostate Cancer

In males over 55 years old finasteride decreases the risk of low-grade prostate cancer but may increase the risk of high-grade prostate cancer and has no effect on overall survival.

A 2010 review found a 25% reduction in the risk of prostate cancer with 5α-reductase inhibitor. A follow-up study of the Medicare claims of participants in a 10-year Prostate Cancer Prevention Trial suggests the reduction in prostate cancer is maintained even after discontinuation of treatment. However, 5α-reductase inhibitors have been found to increase the risk of developing certain rare but aggressive forms of prostate cancer (27% risk increase), although not all studies have observed this. No impact of 5-α-reductase inhibitor on survival has been found in people with prostate cancer.

Excessive Hair Growth

Finasteride has been found to be effective in the treatment of hirsutism (excessive facial and/or body hair growth) in women. In a study of 89 women with hyperandrogenism due to persistent adrenarche syndrome, finasteride produced a 93% reduction in facial hirsutism and a 73% reduction bodily hirsutism after 2 years of treatment. Other studies using finasteride for hirsutism have also found it to be clearly effective.

Transgender Hormone Therapy

Finasteride is sometimes used in hormone replacement therapy for transgender women due to its antiandrogenic effects, in combination with a form of estrogen. However, little clinical research of finasteride use for this purpose has been conducted and evidence of safety or efficacy is limited. Moreover, caution has been recommended when prescribing finasteride to transgender women, as finasteride may be associated with side effects such as depression, anxiety, and suicidal ideation, symptoms that are particularly prevalent in the transgender population and in others at high risk already.



99% High Purity Original Powder Finasteride CAS 98319-26-7 for Hair Loss

99% High Purity Original Powder Finasteride CAS 98319-26-7 for Hair Loss99% High Purity Original Powder Finasteride CAS 98319-26-7 for Hair Loss99% High Purity Original Powder Finasteride CAS 98319-26-7 for Hair Loss99% High Purity Original Powder Finasteride CAS 98319-26-7 for Hair Loss99% High Purity Original Powder Finasteride CAS 98319-26-7 for Hair Loss99% High Purity Original Powder Finasteride CAS 98319-26-7 for Hair Loss